Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clindamycin + hydrocortisone
- Development stage
- Phase 2
- Lead developer
- Sincerus
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Clindamycin + hydrocortisone is a topical combination drug containing clindamycin, a lincosamide antibiotic, and hydrocortisone, a glucocorticoid corticosteroid. Clindamycin acts by binding to the 50S subunit of bacterial ribosomes, inhibiting bacterial protein synthesis and providing antibacterial activity. Hydrocortisone exerts anti-inflammatory effects by acting as an agonist at the glucocorticoid receptor, reducing inflammation in the skin. This combination is primarily used for dermatological conditions where both infection and inflammation are present[1][8]. The product may be formulated as a lotion or cream for topical application.
- Other names
- clindamycin/hydrocortisone lotion
02
Targets
Bacterial 50S ribosomal subunitGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on clindamycin + hydrocortisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clindamycin + hydrocortisone.